Development and Evaluation of Gastro-retentive Floating Tablet of Rilpivirine Hydrochloride for the Treatment of HIV

Dipali Trivedi*, Arti Majumdar, Neelesh Malviya
Smriti College of Pharmaceutical Education, Indore (M.P.), India

ABSTRACT

Besides enormous improvements in drug delivery, oral route has been highly and effectively utilized route of administration. Floating drug delivery that is also known to be low density system is advancement in the class of gastro-retentive drug delivery system. In the present research work, floating drug delivery of Rilpivirine hydrochloride was developed by overcoming various limitations and troubles associated with the drug including poor absorption in intestinal pH and degradation when comes in contact with higher pH environment. Prepared formulations were evaluated for various parameters like friability, hardness, thickness, drug content analysis, floating properties and in-vitro drug release study. Based on the evaluation, concluded that floating drug delivery system is a non-toxic as well as cost-effective technique for the rationale of enhancing bioavailability and absorption of poorly water soluble drugs. The improvement in gastric residence time is a clear sign. It can be able to use in the future for more acidic soluble drugs to enhance solubility and absorption.

Keywords: Floating drug delivery, gastric residence time, Rilpivirine, effervescent, NNRTI.

INTRODUCTION:

A virus that devastate the immune system of the body and causes Acquired Immuno Deficiency Syndrome (AIDS) is Human Immuno-deficiency Virus (HIV). Number of drugs are investigated to be anti-HIV.[1] The drugs like Rilpivirine appears to be most appropriate non- nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 in adults because it has better tolerability which leads to less drug discontinuation and fewer side effects as compared to other NNRTIs.

The main objective of the research work was to design a floating drug delivery system for Rilpivirine hydrochloride. The solubility and systemic absorption of Rilpivirine is pH dependent. It is demonstrated by an increased bioavailability in an acidic environment. [2] To improve the absorption of Rilpivirine by preventing the drug from alkaline environment, floating tablet was prepared.

MATERIALS AND METHODS:

Materials: Rilpivirine hydrochloride was received as a gift sample from Cipla Research and Development, Mumbai. HPMC, Sodium bicarbonate, crospovidone and microcrystalline cellulose were received from Smriti College of Pharmaceutical Education, Indore. Further chemicals used during formulation were analytical grade.

Method:

Preparation of Tablets:
The active ingredient and excipients were weighed accurately and powder blend was directly compressed into tablet with the help of tablet punching machine consisting of 25 mg of Rilpivirine hydrochloride.
Table 1: Composition of Floating Tablet

| Composition                       | F1 (mg) | F2 (mg) | F3 (mg) | F4 (mg) | F5 (mg) | F6 (mg) |
|-----------------------------------|---------|---------|---------|---------|---------|---------|
| Rilpivirine HCl                   | 25      | 25      | 25      | 25      | 25      | 25      |
| HPMC                              | 80      | 80      | 80      | 80      | 80      | 80      |
| Crospovidone                      | 65      | 65      | 65      | 65      | 65      | 65      |
| Microcrystalline cellulose        | 70      | 70      | 85      | 70      | 70      | 70      |
| Magnesium stearate                | 25      | 25      | 25      | 25      | 25      | 25      |
| Sodium bicarbonate                | 60      | 50      | 40      | 40      | 35      | 25      |
| Citric acid                       | 15      | 25      | 20      | 35      | 40      | 50      |
| Lactose                           | 10      | 10      | 10      | 10      | 10      | 10      |
| Total weight                      | 350     | 350     | 350     | 350     | 350     | 350     |

Evaluation of prepared tablets:

Weight variation:

It was carried out to ensure the proper amount of drug in each tablet. 20 tablets were weighed individually with the help of analytical balance. The average weight was calculated and the percent weight variation was calculated with the help formula.

% Weight Variation = (Individual weight - Average weight) / Average weight × 100

Hardness:

The hardness of the tablet was determined with the help of Monsanto hardness tester and expressed in kg/cm².

Diameter and thickness:

The diameter and the thickness of the tablet was measured with the help of vernier caliper and expressed in mm.

Friability:

Tablets equivalent to 6.5 gm were weighed and placed into the apparatus. They were exposed to rolling and repeated shocks as they fall from six inches in each turn within the apparatus. After 4 minutes or 100 revolutions, the tablets were reweighed and the loss due to abrasion was measured. Not more than 1% of the weight of the tablets is acceptable.

% Friability = (W₁ - W₂) / W₁ × 100

Here, W₁ is the initial weight of tablet and W₂ is the final weight of tablet.

Floating properties of prepared formulations:

The formulation was tested for floating properties like floating lag time and total floating time. Tablets were placed in a 100 ml beaker containing 0.1 N HCl (1.2 pH). The time required raising the tablet to the surface and show buoyancy was taken as the floating lag time. The total time interval of the tablet to float on the surface was taken as total floating time.

Drug content:

Tablets were randomly selected and crushed into mortar pestle. A suitable quantity of powder was extracted with 100 ml of 0.1 N HCl. This solution was filtered and analyzed under UV-spectrophotometer (Shimadzu 1800) at 315 nm.

In-vitro drug release:

The drug release from the Rilpivirine hydrochloride floating tablets was investigated in a USP-II (paddle) apparatus. At predestined time intervals, aliquot were withdrawn and then analyzed under UV Spectrophotometer at λ max at 315 nm.

RESULTS:

Table 2: Pre-compression studies of formulated floating tablets

| Formulation Code | Bulk density (gm/mL) ±SD | Tapped Density (gm/mL) ±SD | Carr’s Index (%) ±SD | Hausner’s Ratio | Angle of repose (θ) ±SD |
|------------------|--------------------------|---------------------------|----------------------|----------------|-----------------------|
| F1               | 0.412±0.009              | 0.612±0.014               | 12.7±0.08            | 1.48           | 25.55±0.91           |
| F2               | 0.317±0.01               | 0.367±0.02                | 13.24±0.13           | 1.15           | 22.33±0.88           |
| F3               | 0.374±0.006              | 0.542±0.018               | 11.81±0.18           | 1.44           | 25.55±0.86           |
| F4               | 0.296±0.03               | 0.320±0.03                | 14.65±0.06           | 1.08           | 21.12±0.54           |
| F5               | 0.296±0.03               | 0.391±0.07                | 13.63±0.04           | 1.32           | 26.71±0.46           |
| F6               | 0.327±0.03               | 0.389±0.04                | 14.56±0.04           | 1.18           | 25.07±0.41           |
TABLE 3: Post-compression studies of formulated floating tablets

| Batch Code | Thickness (mm) ±SD | Hardness (Kg/cm²) ±SD | Friability (%) | Weight Variation (%) | Floating Lag time (sec) | Total Floating time (hrs) | Drug Content (%) ±SD |
|------------|-------------------|-----------------------|----------------|----------------------|------------------------|--------------------------|---------------------|
| F1         | 3.23±0.76         | 5.33±0.844            | 0.53           | 2.5±0.661            | 18                     | 22                       | 96.15±1.53          |
| F2         | 3.4±0.41          | 5.41±1.21             | 0.40           | 2.2±0.564            | 19                     | 26.04                    | 97.25±1.71          |
| F3         | 3.36±0.449        | 5±0.894               | 0.65           | 3.5±0.776            | 25                     | 23                       | 95.22±0.91          |
| F4         | 3.53±0.28         | 4.83±1.329            | 0.81           | 3.7±0.913            | 10                     | 24.10                    | 93.17±2.76          |
| F5         | 3.51±0.41         | 5.22±0.983            | 0.47           | 3.1±0.852            | 6                      | 10                       | 92.45±2.15          |
| F6         | 3.46±0.406        | 5.16±2.56             | 0.70           | 3.9±0.987            | 4                      | 4.05                     | 93.27±0.98          |

Figure 1: Floating Tablet

TABLE 4: Drug release profile of formulated floating tablets

| Time (hrs) | Cumulative Drug Release of Prepared Formulation |
|------------|-----------------------------------------------|
|            | Batch 1 | Batch 2 | Batch 3 | Batch 4 | Batch 5 | Batch 6 |
| 0.5 hr     | 9.1±0.12 | 9.3±1.6 | 10.1±0.7 | 11.1±1.1 | 11.8±1.1 | 15.4±0.7 |
| 1 hr       | 14.1±1.8 | 13.3±1.4 | 13.8±0.7 | 14.1±1.4 | 16.2±1.77 | 18.4±1.5 |
| 2 hr       | 20.6±0.6 | 21.2±2.7 | 20.1±1.7 | 19.2±0.8 | 23.6±1.7 | 25.4±0.75 |
| 3 hr       | 31.5±0.9 | 33.6±2.2 | 30.7±2.1 | 28.1±1.8 | 31.3±0.9 | 37.9±0.86 |
| 4 hr       | 39.2±0.9 | 41.8±1.9 | 38.9±1.2 | 37.5±0.8 | 43.6±2.6 | 42.9±2.31 |
| 5 hr       | 45.5±2.6 | 49.6±1.1 | 45.1±1.7 | 43.1±1.1 | 55.1±0.5 | 55.2±1.82 |
| 6 hr       | 56.9±3.2 | 54.9±1.3 | 53.8±0.7 | 51.7±2.2 | 60.3±1.7 | 61.6±0.12 |
| 18 hr      | 70.7±1.6 | 76.7±1.4 | 64.5±1.2 | 72.8±2.9 | 72.4±1.5 | 79.5±0.14 |
| 20 hr      | 82.2±0.8 | 87.7±1.9 | 83.6±1.2 | 80.4±2.3 | 83.2±2.21 | 85.2±0.91 |
| 24 hr      | 90.7±0.59 | 94.8±0.81 | 90.0±0.98 | 89.9±0.84 | 94.5±0.99 | 97.6±1.51 |
Dissolution study of formulated batches:
The dissolution study of floating tablets were performed in 0.1 N HCl (1.2 pH) and observed results are depicted in the graph (Figure 2).

**DISCUSSION:**
In this research work, the effervescent floating tablets of Rilpivirine HCl were successfully formulated using citric acid and sodium bicarbonate as gas forming agent and HPMC as film forming polymer. The identification tests of Rilpivirine HCl drug sample was done with the help of UV analysis, melting point determination, solubility studies, and IR and DSC tests. The observations recorded were identical to the values reported in literature. The evaluations of prepared floating tablet reveal encouraging result, because the prolonged gastric residence time is an enhancement in bioavailability. The optimized batch (F2) gave the best result in terms of in-vitro drug release rate and floating duration (>24 hrs). Sodium bicarbonate and citric acid were used in the ratio of 2:1 in optimized batch (F2), the release rate of this formulation was gradual enough to prolong the drug delivery and absorbed in gastric fluid.

**REFERENCES:**
1. Reeves J, Doms R. Human Immuno-deficiency Virus. Journal of General Virology. 2002; 83(6):1253-1265.
2. Sharma M, Louis D. Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor. Journal of Antimicrobial Chemotherapy. 2012; 68:250-256.
3. Bhatti A, Usman M, Kandi V. Current scenario of HIV/AIDS, treatment options, and major challenges with compliance to antiretroviral therapy. Cureus Publishing. 2016; 8(3):1-12.
4. Baumgartner S, Kristl J, Vrecer F. Optimization of floating matrix tablet and evaluation of their gastric residence time. International Journal of Pharmaceutics. 1999; 195(2000):125-135.
5. Ansel CH, Loyd V. Pharmaceutical dosage form and drug delivery system. International Journal of Pharmaceutical compounding. 9th edition, 2011.
6. Vyas SP, Khar R. Controlled Drug Delivery concepts and advances. 2nd edition, 2012.
7. Dubey J, Verma N. Floating Drug Delivery System: A Review. International Journal of Pharmaceutical Science and Research. 2013; 4(8):2893-2899.
8. Tripathi J, Thapa P. A review on current state and future perspective on GRDDS. MDPI. 2019; 11(4):6-16.
9. Kommarapur P, Sunkara M. Preparation and characterization of Rilpivirine solid dispersion with application of enhanced solubility and dissolution rate. Beni-Suef University Journal of Basic and Applied Sciences. 2015; 4:1-2.
10. Ramesh, K. Micronization and formulation for improvement of rate of dissolution of Rilpivirine. Beni-Suef University Journal of Basic and Applied Sciences. 2015; 4:1-2.